126 related articles for article (PubMed ID: 38484250)
21. Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States.
Goldman HB; Anger JT; Esinduy CB; Zou KH; Russell D; Luo X; Ntanios F; Carlsson MO; Clemens JQ
Urology; 2016 Jan; 87():64-9. PubMed ID: 26436212
[TBL] [Abstract][Full Text] [Related]
22. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
23. Fluid intake behavior in women with refractory overactive bladder undergoing third line therapy.
Zhao K; Harandi AA; Ramgopal J; Kim J; Weissbart S
Neurourol Urodyn; 2024 Jan; 43(1):44-51. PubMed ID: 37961997
[TBL] [Abstract][Full Text] [Related]
24. Urodynamics less likely to change diagnosis and management in uncomplicated overactive bladder.
English K; Maiman R; Laudano M; Abraham N
Can J Urol; 2020 Jun; 27(3):10244-10249. PubMed ID: 32544048
[TBL] [Abstract][Full Text] [Related]
25. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).
El-Zawahry A
Curr Urol Rep; 2019 May; 20(6):33. PubMed ID: 31098731
[TBL] [Abstract][Full Text] [Related]
26. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
27. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
28. Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; van Amerongen D
Am J Alzheimers Dis Other Demen; 2019; 34(7-8):492-499. PubMed ID: 30966757
[TBL] [Abstract][Full Text] [Related]
29. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
[TBL] [Abstract][Full Text] [Related]
30. Electrical stimulation with non-implanted electrodes for overactive bladder in adults.
Stewart F; Gameiro LF; El Dib R; Gameiro MO; Kapoor A; Amaro JL
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010098. PubMed ID: 27935011
[TBL] [Abstract][Full Text] [Related]
31. Patient navigation for overactive bladder improves access to care.
Rohloff M; Peifer G; Thompson JH
Int Urogynecol J; 2020 May; 31(5):1007-1012. PubMed ID: 31463529
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
[TBL] [Abstract][Full Text] [Related]
33. Overactive bladder medication: Persistence, drug switching, and reinitiation.
Soda T; Tashiro Y; Koike S; Ikeuchi R; Okada T
Neurourol Urodyn; 2020 Nov; 39(8):2527-2534. PubMed ID: 32985716
[TBL] [Abstract][Full Text] [Related]
34. [Current state of diagnostics and treatment of overactive bladder in the Czech Republic - five years ago and today].
Krhut J; Martan A; Zachoval R; Tvrdík J; Hanus T
Ceska Gynekol; 2012 Jun; 77(3):205-10. PubMed ID: 22779719
[TBL] [Abstract][Full Text] [Related]
35. Transcutaneous tibial nerve electrical stimulation versus vaginal electrical stimulation in women with overactive bladder syndrome: Is there a role for short-term interventions?
Nunes JMO; Gregório EP; Moreira ECH; Hazime FA; Averbeck MA; de Almeida SHM
Neurourol Urodyn; 2023 Jun; 42(5):1101-1110. PubMed ID: 37042223
[TBL] [Abstract][Full Text] [Related]
36. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and associated symptom improvement during six months of care for overactive bladder: a prospective, observational study.
Boone TB; Kusek JW; Nyberg LM; Steele G; Pashos C; Grossman M; Diokno A; Bull S; Albrecht D
Clin Ther; 2002 Mar; 24(3):397-408. PubMed ID: 11952023
[TBL] [Abstract][Full Text] [Related]
38. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
39. How does site of pelvic organ prolapse repair affect overactive bladder symptoms?
Dieter AA; Edenfield AL; Weidner AC; Siddiqui NY
Female Pelvic Med Reconstr Surg; 2014; 20(4):203-7. PubMed ID: 24978085
[TBL] [Abstract][Full Text] [Related]
40. Changes in overactive bladder medication following bariatric surgery: segmented regression analysis.
Al-Bahou J; Bhagwandass H; Valdes IL; Friedman J; Vouri SM
World J Urol; 2022 Jul; 40(7):1777-1783. PubMed ID: 35384485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
